Prion Protein, aa109-112 (PrP, CD230) (APC)

Referentie P8950-10-APC-100ul

Formaat : 100ul

Merk : US Biological

Meer informatie aanvragen

Neem contact op met een lokale distributeur :


Telefoonnummer : +1 850 650 7790


P8950-10-APC Prion Protein, aa109-112 (PrP, CD230) (APC)

Clone Type
Polyclonal
Host
mouse
Source
human
Swiss Prot
P04156
Isotype
IgG2a
Grade
Affinity Purified
Applications
E IHC IP WB
Crossreactivity
Fe Hm Hu
Accession #
NM_000311.3
Shipping Temp
Blue Ice
Storage Temp
4°C Do Not Freeze

The prion protein is a large membrane protein that occurs normally in neurons of the human brain and is thought to be involved in synaptic transmission. In prion diseases, such as CJD, Gerstmann-Straussler-Scheinker syndrome (GSS), Fatal Familial Insomnia (FFI), Alpers Syndrome and Kuru, the normal cellular form of this protein (PrPc) is transformed into an altered protein when it comes into contact with an infectious prion protein (PrPsc) from another host. This altered PrPsc accumulates in cytoplasmic vesicles of diseased individuals forming lesions, vacuoles and amyloid deposits.||Applications:|Suitable for use in Immunohistochemistry, Western Blot, Immunoprecipitation and ELISA. Other applications have not been tested.||Recommended Dilution:|Immunohistochemistry (parrafin): 1:100-1:1000 Requires citrate buffer (HIER). Immunoreactivity is seen predominantly as cell body staining of neurons. Epitope must be re-exposed in fixed tissue by pretreatment of tissue using one of the following procedures: |a. formic acid for 10 minutes at RT |b. hydrolytic autoclaving |c. microwaving |Western Blot: 1:10,000-1:100,000|Immunoprecipitation: 1:10-1:100|ELISA: ≥ 1:100,000|Optimal dilutions to be determined by the researcher.||Recommended Control: |Brain tissue||Storage and Stability:|Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: APC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap. ||Note: Applications are based on unconjugated antibody.

Applications
Product Type: Mab|Isotype: IgG2a|Clone No: 2Q126 (3F4)|Host: mouse|Source: human|Concentration: As Reported |Form: Supplied as a liquid in PBS, pH 7.2. Labeled with Allophycocyanin (APC).|Purity: Purified by Protein A affinity chromatography.|Immunogen: Synthetic peptide corresponding to aa109-112 of human prion protein.|Specificity: Recognizes Prion protein, aa109-112. Recognizes native and denatured forms of PrP. Recognizes both protease sensitive and protease resistant forms of PrP (after denatured). |Species Crossreactivity: Human, hamster and feline. Does not react with PrP from any other mammalian species.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Synthetic peptide corresponding to aa109-112 of human prion protein.
Form
Supplied as a liquid in PBS, pH 7.2. Labeled with Allophycocyanin (APC).
Purity
Purified by Protein A affinity chromatography.
Specificity
Recognizes Prion protein, aa109-112. Recognizes native and denatured forms of PrP. Recognizes both protease sensitive and protease resistant forms of PrP (after denatured). |Species Crossreactivity: Human, hamster and feline. Does not react with PrP from any other mammalian species.
References
1. Kitamoto, T., et al., Lab Invest. 57: 230-236 (1987). 2. Kascsak, et al.,, J. Virol. 61: 3688-3693 (1987). 3. Kitamoto, T., et al., J. Virol. 65: 6292-6295 (1991). 4. Kascsak, et al., Dev. Biol. Stand. 80: 141-151| (1993). 5. Kascsak, R.J., et al., 26(1-2): 259-268 (1997). 6. Safar, J., et al., Nat. Med. 4(10): 1157-1165 (1998). 7. Rubenstein, R., et al., J. Neurovirol. 5(4): 401-413 (1999). 8. Aucouturier, P., et al., Neurosci. Letter 274(1): 33-36. (1999). 9. Lee, D.C., et al., J. Virol. Methods 84(1): 77-89 (2000). 10. Soto, C., et al., Lancet 355(9199): 192-197 (2000). 11. Carp, R.I., et al., J. Neurovirol. 6(2): 137-144 (2000).